Expression of CD80/CD86 and CTLA-4 mRNA in peripheral blood mononuclear cells of the patients with systemic lupus erythematosus

Abstract

The role of CD80/CD86 and CTLA-4 in the pathogenesis of systemic lupus erythematosus and their clinical significance was investigated. By using RT-PCR technique, the expression of CD80/CD86 and CTLA-4 mRNA in peripheral blood mononuclear cells (PBMC) were semiquantitatively detected in 32 patients with active SLE. The results showed that the percentage of positive CD86 expression in active SLE was increased significantly as compared with normal controls (90.63% vs 60.00%,P<0.01). The mean level of CD86 mRNA expression in active SLE group was markedly higher than in the normal controls (0.6410+0.0174 vs 0.4510+0.0402,P<0.001). Compared with normal controls, the percentage of positive CTLA-4 expression and the mean level of CTLA-4 mRNA expression in active SLE group were both increased significantly (bothP<0.01). There was no statistical differences in positive rate of CD80 and the average level of CD80 mRNA between the two groups (bothP>0.05). It was concluded that the aberrant expression of CD86 and CTLA-4 might play an important role in the activity and development of SLE.

Keywords

lupus erythematosus / systemic / antigen / CD80 / CD86 / CTLA-4

References

[1] BijlM, HorstG, LimburgP C, et al. . Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis, 2001, 60(5): 523-523

[2] NagafuchiH, ShimoyamaY, KashiwakuraJ, et al. . Enhanced CD86 expression of B cells by CD40L is essential for polyclonal antibody production. Clin Exp Rheumatol, 2003, 21(1): 71-71

[3] BombardierC, GladmanD D, UrowitzM B, et al. . Derivation of the SLEDAI: a disease activity index for lupus patients: The Committee on prognosis studies in SLE. Arthritis Rheum, 1992, 35630-630

[4] GuerderS, MeyerhoffJ, FlavellR. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity, 1994, 1155-155

[5] SchweitzerA N, SharpeA H. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J Immunol, 1998, 1612762-2762

[6] FunauchiM, YooB S, NozakiY, et al. . Lupus dysregulation of the granulocyte-macrophage colony-stimulating factor receptor is one of the causes of defective expression of CD80 antigen in systemic lupus erythematosus, 2002, 11(5): 317-317

[7] DenfeldR W, KindP, SontheimerR D, et al. . In situ expression of B7 and CD28 receptor families in skin lesions of patients with lupus erythematosus. Arthritis Rheum, 1997, 40(5): 814-814

[8] LeeK M, ChuangE, GriffinM, et al. . Molecular basis of T cell inactivation by CTLA-4. Science, 1998, 2822263-2263

[9] KhatlaniT S, MaZ, OkudaM, et al. . Autoantibodies against T-Cell costimulatory molecules are produced in canine autoimmune diseases. J Immunother, 2003, 26(1): 12-12

[10] OaksM K, HallettK M. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol, 2000, 1645015-5015